312 related articles for article (PubMed ID: 14719993)
21. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study.
Sermet-Gaudelus I; Renouil M; Fajac A; Bidou L; Parbaille B; Pierrot S; Davy N; Bismuth E; Reinert P; Lenoir G; Lesure JF; Rousset JP; Edelman A
BMC Med; 2007 Mar; 5():5. PubMed ID: 17394637
[TBL] [Abstract][Full Text] [Related]
22. In vitro pharmacologic restoration of CFTR-mediated chloride transport with sodium 4-phenylbutyrate in cystic fibrosis epithelial cells containing delta F508-CFTR.
Rubenstein RC; Egan ME; Zeitlin PL
J Clin Invest; 1997 Nov; 100(10):2457-65. PubMed ID: 9366560
[TBL] [Abstract][Full Text] [Related]
23. Pharmacological treatment of the basic defect in cystic fibrosis.
Roomans GM
Cell Biol Int; 2014 Nov; 38(11):1244-6. PubMed ID: 24809326
[TBL] [Abstract][Full Text] [Related]
24. Repairing the basic defect in cystic fibrosis - one approach is not enough.
Farinha CM; Matos P
FEBS J; 2016 Jan; 283(2):246-64. PubMed ID: 26416076
[TBL] [Abstract][Full Text] [Related]
25. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
[TBL] [Abstract][Full Text] [Related]
26. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease.
Moore PJ; Tarran R
Expert Opin Ther Targets; 2018 Aug; 22(8):687-701. PubMed ID: 30028216
[TBL] [Abstract][Full Text] [Related]
27. Pharmacologic treatment of abnormal ion transport in the airway epithelium in cystic fibrosis.
Knowles MR; Olivier KN; Hohneker KW; Robinson J; Bennett WD; Boucher RC
Chest; 1995 Feb; 107(2 Suppl):71S-76S. PubMed ID: 7842817
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic approaches to CFTR dysfunction: From discovery to drug development.
Li H; Pesce E; Sheppard DN; Singh AK; Pedemonte N
J Cyst Fibros; 2018 Mar; 17(2S):S14-S21. PubMed ID: 28916430
[TBL] [Abstract][Full Text] [Related]
29. Pharmacogenomics of the cystic fibrosis transmembrane conductance regulator (CFTR) and the cystic fibrosis drug CPX using genome microarray analysis.
Srivastava M; Eidelman O; Pollard HB
Mol Med; 1999 Nov; 5(11):753-67. PubMed ID: 10656877
[TBL] [Abstract][Full Text] [Related]
30. Mutation specific therapy in CF.
Kerem E
Paediatr Respir Rev; 2006; 7 Suppl 1():S166-9. PubMed ID: 16798551
[TBL] [Abstract][Full Text] [Related]
31. Deletion of phenylalanine 508 causes attenuated phosphorylation-dependent activation of CFTR chloride channels.
Wang F; Zeltwanger S; Hu S; Hwang TC
J Physiol; 2000 May; 524 Pt 3(Pt 3):637-48. PubMed ID: 10790148
[TBL] [Abstract][Full Text] [Related]
32. Expression of delta F508 cystic fibrosis transmembrane conductance regulator protein and related chloride transport properties in the gallbladder epithelium from cystic fibrosis patients.
Dray-Charier N; Paul A; Scoazec JY; Veissière D; Mergey M; Capeau J; Soubrane O; Housset C
Hepatology; 1999 Jun; 29(6):1624-34. PubMed ID: 10347100
[TBL] [Abstract][Full Text] [Related]
33. The cystic fibrosis mutation G1349D within the signature motif LSHGH of NBD2 abolishes the activation of CFTR chloride channels by genistein.
Melin P; Thoreau V; Norez C; Bilan F; Kitzis A; Becq F
Biochem Pharmacol; 2004 Jun; 67(12):2187-96. PubMed ID: 15163550
[TBL] [Abstract][Full Text] [Related]
34. Lack of correlation between CFTR expression, CFTR Cl- currents, amiloride-sensitive Na+ conductance, and cystic fibrosis phenotype.
Beck S; Kühr J; Schütz VV; Seydewitz HH; Brandis M; Greger R; Kunzelmann K
Pediatr Pulmonol; 1999 Apr; 27(4):251-9. PubMed ID: 10230924
[TBL] [Abstract][Full Text] [Related]
35. A truncated CFTR protein rescues endogenous DeltaF508-CFTR and corrects chloride transport in mice.
Cormet-Boyaka E; Hong JS; Berdiev BK; Fortenberry JA; Rennolds J; Clancy JP; Benos DJ; Boyaka PN; Sorscher EJ
FASEB J; 2009 Nov; 23(11):3743-51. PubMed ID: 19620404
[TBL] [Abstract][Full Text] [Related]
36. Relationships between cystic fibrosis transmembrane conductance regulator, extracellular nucleotides and cystic fibrosis.
Marcet B; Boeynaems JM
Pharmacol Ther; 2006 Dec; 112(3):719-32. PubMed ID: 16828872
[TBL] [Abstract][Full Text] [Related]
37. Curcumin does not stimulate cAMP-mediated chloride transport in cystic fibrosis airway epithelial cells.
Dragomir A; Björstad J; Hjelte L; Roomans GM
Biochem Biophys Res Commun; 2004 Sep; 322(2):447-51. PubMed ID: 15325250
[TBL] [Abstract][Full Text] [Related]
38. Ion channels as targets to treat cystic fibrosis lung disease.
Martin SL; Saint-Criq V; Hwang TC; Csanády L
J Cyst Fibros; 2018 Mar; 17(2S):S22-S27. PubMed ID: 29102290
[TBL] [Abstract][Full Text] [Related]
39. Effects of purinergic stimulation, CFTR and osmotic stress on amiloride-sensitive Na+ transport in epithelia and Xenopus oocytes.
Schreiber R; König J; Sun J; Markovich D; Kunzelmann K
J Membr Biol; 2003 Mar; 192(2):101-10. PubMed ID: 12682798
[TBL] [Abstract][Full Text] [Related]
40. Activation of CFTR by genistein in human airway epithelial cell lines.
Andersson C; Servetnyk Z; Roomans GM
Biochem Biophys Res Commun; 2003 Aug; 308(3):518-22. PubMed ID: 12914781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
